Please wait while we load the requested 10-K report or click the link below:
https://last10k.com/sec-filings/report/1612630/000117184319001609/f10k_030819p.htm
March 2023
March 2023
November 2022
August 2022
May 2022
May 2022
May 2022
March 2022
February 2022
November 2021
EXHIBIT 99.1
The Joint Corp. Reports Fourth Quarter and Full Year 2018 Financial Results
- Increases Annual System-Wide Gross Sales 30%, Compared to 2017 -
- Achieves Positive Annual Net Income for the First Time of $253,000 -
- Sells 99 Franchise Licenses in 2018, Up from 37 in 2017 -
SCOTTSDALE, Ariz., March 07, 2019 (GLOBE NEWSWIRE) -- The Joint Corp. (NASDAQ: JYNT), a national operator, manager and franchisor of chiropractic clinics, reported financial results for the fourth quarter and full year ended December 31, 2018.
Fourth Quarter Highlights: 2018 Compared to 2017
2018 Financial Highlights
Recent Operating Achievements
Please wait while we load the requested 10-K report or click the link below:
https://last10k.com/sec-filings/report/1612630/000117184319001609/f10k_030819p.htm
Compare this 10-K Annual Report to its predecessor by reading our highlights to see what text and tables were removed , added and changed by Joint Corp.
Joint Corp's Definitive Proxy Statement (Form DEF 14A) filed after their 2019 10-K Annual Report includes:
Rating
Learn More![]()
Depreciation and amortization expenses decreased for the year ended December 31, 2018, as compared to the year ended December 31, 2017, primarily due to the impairment of previously depreciating assets as part of our change in IT strategy.
We will continue to preserve cash, and while we plan to resume the acquisition and development of company-owned or managed clinics, we intend to progress at a measured pace and target geographic clusters where we are able to increase efficiencies through a consolidated real estate penetration strategy, leverage cooperative advertising and marketing and attain general corporate and administrative operating efficiencies.
Corporate Clinics Revenues and management fees from company-owned or managed clinics increased, primarily due to improved same-store sales growth, and the addition of one company-managed clinic during the year.
Regional developer fees paid to the Company are nonrefundable and are recognized as revenue ratably on a straight-line basis over the term of the regional developer agreement, which is considered to begin upon the execution of the agreement.
This increase was primarily driven by: An increase in revenues of approximately $3.5 million from company-owned or managed clinics; and A decrease of approximately $0.5 million in depreciation and amortization, primarily due to the impairment of previously depreciating assets as part of our change in IT strategy; offset by An increase of approximately $0.3 million of selling and marketing expenses and $0.6 million in general and administrative costs primarily due to wage merit increases and accrued bonus for the 2018 period.
Further, cash and cash equivalents...Read more
Software fees revenue increased due...Read more
Components of revenues for the...Read more
Selling and marketing expenses increased...Read more
Regional developer fees increased due...Read more
Certain income tax effects of...Read more
For the years ended December...Read more
We adopted the new standard...Read more
We believe that The Joint...Read more
We require the entire non-refundable...Read more
For the year ended December...Read more
In addition, we believe that...Read more
We continue to deliver on...Read more
28 Our current strategy is...Read more
Therefore, we recognize revenue under...Read more
Intangible assets consist primarily of...Read more
General and administrative expenses increased...Read more
29 Goodwill consists of the...Read more
These trends join with the...Read more
For the year ended December...Read more
Our services under regional developer...Read more
As a result of the...Read more
Changes to the assumptions could...Read more
Goodwill and intangible assets deemed...Read more
On November 18, 2014, our...Read more
On December 30, 2015, our...Read more
See Note 1, Nature of...Read more
For the year ended December...Read more
Financial Statements, Disclosures and Schedules
Inside this 10-K Annual Report
Material Contracts, Statements, Certifications & more
Joint Corp provided additional information to their SEC Filing as exhibits
Ticker: JYNT
CIK: 1612630
Form Type: 10-K Annual Report
Accession Number: 0001171843-19-001609
Submitted to the SEC: Fri Mar 08 2019 12:32:30 PM EST
Accepted by the SEC: Mon Mar 11 2019
Period: Monday, December 31, 2018
Industry: Patent Owners And Lessors